We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

First-of-Its-Kind Molecular Karyotyping Test Assists Hematologists in Diagnosing Leukemia

By LabMedica International staff writers
Posted on 11 Apr 2022
Print article
Image: LeukoPrint is a first-in-class leukemia sWGS CNA test (Photo courtesy of SeekIn Inc.)
Image: LeukoPrint is a first-in-class leukemia sWGS CNA test (Photo courtesy of SeekIn Inc.)

Leukemias are a group of life threatening malignant disorders of the blood and bone marrow, which can occur at any age. There are a total of ~ 4.4 million new cases of and ~ 3.1 million deaths from leukemia worldwide annually. Genomic alternations, especially copy number aberrations (CNAs), are particularly imperative for diagnostic classification and risk stratification in leukemia patients. The conventional cytogenetic analysis, karyotyping, has been used to detect the genetic alterations of the hematopoietic malignancies for decades. Although karyotyping can provide a panoramic view of chromosomal aberrations, this technique comes with several drawbacks, such as a time-consuming and prone-to-failure cell-culturing step, relatively low resolution which is usually unable to detect submicroscopic changes (< 10 Mb), and a visual interpretation that is highly dependent on cytogeneticist experience and knowledge of the disease. Now, a new test kit can evaluate the CNA in bone marrow cells and/or circulating cell-free DNA (cfDNA) via shallow whole-genome sequencing (sWGS), in combination with conventional cytogenetics technologies, to make leukemia diagnosis, molecular subtyping, prognostic stratification and treatment response monitoring more precise and comprehensive.

SeekIn Inc. (Shenzhen, China) has developed the LeukoPrint Molecular Karyotyping Kit which can help hematologists make diagnosis and prognostic stratification according to European Leukemia Net (ELN), Revised International Prognostic Scoring System (IPSS-R) or Revised International Staging System (R-ISS) guidelines. Except for leukemias, LeukoPrint is also applicable to other types of hematological malignancies such as multiple myeloma. The significant advantage of LeukoPrint is high accuracy, high sensitivity, and patients can avoid the pain of frequent sampling from bone marrow. SeekIn has received the CE (Conformité Européenne) Mark for LeukoPrint Molecular Karyotyping Kit and is now ready to launch the test in the European markets.

"With the advent of new DNA sequencing technologies, next-generation sequencing (NGS) based genetic testing has been implemented as a routine protocol for cancer diagnosis, risk stratification, and treatment response evaluation," said Mao Mao, M.D., Ph.D., SeekIn's founder and CEO. "LeukoPrint provides a cost-effective and simplified method for prompt and accurate CNA profiling in leukemia patients. It utilizes a standardized protocol which can be readily extended to clinical laboratories worldwide. With the advantage of detecting CNAs of short DNA fragments, by incorporating with the routine diagnostic methods, LeukoPrint can benefit the conventional cytogenetics by improving diagnostic yield. CE Marking represents a significant milestone for SeekIn in bringing LeukoPrint test to the patients and healthcare providers in Europe. We will continue our efforts to meet additional regulatory requirements in Europe, and to obtain regulatory approvals in the other territories such as China."

Related Links:
SeekIn Inc. 

Gold Supplier
COVID-19 Immune Response Test
Quan-T-Cell
New
Washer Dispenser
EL406
New
Gold Supplier
NT-proBNP Quantitative Antigen Test
NT-proBNP-CHECK-1
New
Automatic Photometer
JOLLY 103

Print article

Channels

Clinical Chem.

view channel
Image: The analysis pipeline used to investigate associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease (Photo courtesy of University College London)

Lipid Measurements Show Potential as Alzheimer’s Disease Biomarkers

Brain changes accompanying ageing are varied and can include pathologies that lead to cognitive impairment, the commonest of which is Alzheimer’s disease (AD). Identifying blood-based signatures of brain... Read more

Molecular Diagnostics

view channel
Image: This image depicts a DNA molecule that is methylated on both strands on the center cytosine. DNA methylation plays an important role for epigenetic gene regulation in development and cancer (Photo courtesy of Wikimedia Commons)

Study Supports Use of Methylated DNA Biomarkers for Cancer Diagnosis and Prognosis

A recent study added weight to the theory that methylated DNA biomarkers could be used for cancer diagnosis and prognosis. Methylation is a biological process by which methyl groups are added to a DNA molecule.... Read more

Industry

view channel
Image: QIAGEN has acquired a majority stake in enzymes provider BLIRT S.A. (Photo courtesy of QIAGEN)

Qiagen Acquires Enzymes Provider Blirt to Strengthen Sample Technologies Business

QIAGEN N.V. (Venlo, Netherlands) has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A. (Gdansk, Poland), a manufacturer of recombinant enzymes for the life science industry.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.